Latest news
Search news stories
Enter a keyword to search news.
Professor Jose Polo appointed as EMBL Australia Scientific Head
SAiGENCI's Professor Jose Polo has been appointed as the new Scientific Head of EMBL Australia.
[Read more about Professor Jose Polo appointed as EMBL Australia Scientific Head]
SAiGENCI researcher awarded funding in latest MRFF round
A SAiGENCI project using nanotechnology has received funding in the latest round of Medical Research Future Fund (MRFF) Early-to-Mid Career Researchers funding.
[Read more about SAiGENCI researcher awarded funding in latest MRFF round]
Lorne Cancer Conference 2025
The South Australian immunoGENomics Cancer Institute (SAiGENCI) and Adelaide Centre for Epigenetics (ACE) were well represented at the 37th annual Lorne Cancer Conference held from the 13th to 15th of February in Lorne, a coastal town on the Great Ocean Road in Victoria.
New role brings hope for SA cancer patients
Eradicating cancer from being a terminal disease to one we can successfully manage and treat is the holy grail of cancer research – and the grand vision of a new Molecular Cancer Pathology Fellow being co-funded by The Hospital Research Foundation Group.
[Read more about New role brings hope for SA cancer patients]
SAiGENCI researcher granted national health funding
SAiGENCI research into using PROTACs for cancer treatments has been funded in the latest round of the National Health and Medical Research Council (NHMRC) Investigator Grants.
[Read more about SAiGENCI researcher granted national health funding]
SAiGENCI researchers given a funding boost
Researchers from the South Australian immunoGENomics Cancer Institute (SAiGENCI), based at the University of Adelaide, have been awarded funding to further their work in prostate and pancreatic cancers.
[Read more about SAiGENCI researchers given a funding boost]
SAiGENCI researchers awarded funding through NHMRC program
Two SAiGENCI research groups are among nine from the Faculty of Health and Medical Sciences awarded funding through the latest round of the National Health and Medical Research Council (NHMRC) Ideas Grants.
[Read more about SAiGENCI researchers awarded funding through NHMRC program]
Developing the first drug for multi-organ radiation protection
A pharmaceutical breakthrough at the University of Adelaide is showing promise in both multi-organ radiation protection and cancer treatment.
[Read more about Developing the first drug for multi-organ radiation protection]
SAiGENCI supporter repairs bicycles to support prostate cancer research
Richard Dopheide’s younger brother was only 65 years old when his life was taken by cancer. This tragedy was the motivating force behind Richard’s decision to repair and sell bicycles to raise funds for cancer research.
[Read more about SAiGENCI supporter repairs bicycles to support prostate cancer research]
Meet our researchers: Dharmesh D Bhuva
Dr Dharmesh D Bhuva, Postdoctoral Research Fellow, South Australian ImmunoGENomics Cancer Institute (SAiGENCI).
